SEARCH

SEARCH BY CITATION

References

  • 1
    Mouthon L, Kaveri SV, Spalter SH et al Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996;104:3 9.
  • 2
    Smiley JD & Talbert MG. High-dose intravenous gamma globulin therapy: How does it work? Am J Med Sci 1995;309:295 303.
  • 3
    Arnout J, Spitz B, Wittevrongel C, Vanrusselt M, Vanassche A, Vermylen J. High-dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: immunological changes associated with a successful outcome. Thromb Haemost 1994;71:741 7.
  • 4
    Coulam CB. Immunotherapy with intravenous immunoglobulin for treatment of recurrent pregnancy loss: American experience. Am J Reprod Immunol 1994;32:286 9.
  • 5
    Spinnato JA, Clark AL, Pierangeli SS, Harris EN. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol 1995;172:690 4.
  • 6
    Valensise H, Vaquero E, Decarolis C et al Normal fetal growth in women with antiphospholipid syndrome treated with high-dose intravenous immunoglobulin (IVIG). Prenat Diagn 1995;15:509 17.
  • 7
    Coulam CB, Krysa L, Stern JJ, Bustillo M. Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Am J Reprod Immunol 1995;34:333 7.
  • 8
    Carp HJA, Ahiron R, Mashiach S, Schonfeld Y, Gazit E, Toder V. Intravenous immunoglobulin in women with five or more abortions. Am J Reprod Immunol 1996;35:360 2.
  • 9
    Kiprov DD, Nachtigall RD, Weaver RC, Jacobson A, Main EK, Garovoy MR. The use of intravenous immunoglobulin in recurrent pregnancy loss associated with combined alloimmune and autoimmune abnormalities. Am J Reprod Immunol 1996;36:228 34.
  • 10
    De Carolis C, Vaquero E, Miriello D et al Successful high dose intravenous immunoglobulins (IVIG) treatment in recurrent autoimmune or alloimmune spontaneous abortion. Int J Immunopathol Pharmacol 1997;10:125 31.
  • 11
    Zingsem J, Eckstein R, Mallmann P et al Intravenous immunoglobulin in the prevention of recurrent miscarriage. Br J Obstet Gynaecol 1994;101:1072 7.
  • 12
    Muellereckhardt G. Immunotherapy with intravenous immunoglobulin for prevention of recurrent pregnancy loss: European experience. Am J Reprod Immunol 1994;2:281 5.
  • 13
    Christiansen OB, Mathiesen O, Husth M et al Placebo-controlled trial of treatment of unexplained secondary recurrent spontaneous abortions and recurrent late spontaneous abortions with iv immunoglobulin. Hum Reprod 1995;10:2690 5.
  • 14
    Clark AL & Gall SA. Clinical uses of intravenous immunoglobulin in pregnancy. Am J Obstet Gynecol 1997;176:241 53.
  • 15
    Dalakas MC, Illa I, Dambrosia JM et al A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993 2000.
  • 16
    Basta M & Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729 35.
  • 17
    Nielsen EW, Johansen HT, Gaudesen O et al C3 is activated in hereditary angioedema, and C1/C1- inhibitor complexes rise during physical stress in untreated patients. Scand J Immunol 1995;42:679 85.
  • 18
    Nielsen EW, Johansen HT, Straume B, Mollnes TE. Effect of time, temperature and additives on a functional assay of C1 inhibitor. J Immunol Methods 1994;173:245 51.
  • 19
    Mollnes TE, Høgåsen K, Hoaas BF, Michaelsen TE, Garred P, Harboe M. Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its Cl binding properties. Scand J Immunol 1995;41:449 56.
  • 20
    Fure H, Nielsen EW, Hack CE, Mollnes TE. A neoepitope-based enzyme immunoassay for quantification of C1 inhibitor in complex with C1r and C1s. Scand J Immunol 1997;46:553 7.
  • 21
    Nuijens JH, Huijbregts CC, Eerenberg Belmer AJ et al Quantification of plasma factor XIIa-Cl-inhibitor and kallikrein-Cl-inhibitor complexes in sepsis. Blood 1988;72:1841 8.
  • 22
    Wolbink GJ, Bollen J, Baars JW et al Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods 1993;163:67 76.
  • 23
    Mollnes TE. Analysis of in vivo complement activation. In: Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C, eds. Weir's Handbook of Experimental Immunology, 5th edn. Boston: Blackwell Science Ltd, 1997;78:1 8.
  • 24
    Bergh K & Iversen OJ. Production of monoclonal antibodies against the human anaphylatoxin-C5a des Arg and their application in the neoepitope-specific sandwich-ELISA for the quantification of C5a des Arg in plasma. J Immunol Methods 1992;152:79 87.
  • 25
    Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 1994;97:79 83.
  • 26
    Nydegger UE. Safety and side effects of i.v. immunoglobulin therapy. Clin Exp Rheumatol 1996;14:S53 7.
  • 27
    Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989;84:1974 81.
  • 28
    Berger M, Rosenkranz P, Brown CY. Intravenous and standard immune serum globulin preparations interfere with uptake of 125-I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activity. Clin Immunol Immunopathol 1985;34:227 36.
  • 29
    Mollnes TE, Andreassen IH, Høgåsen K, Hack CE, Harboe M. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro. Mol Immunol 1997;34:719 29.
  • 30
    Lutz HU, Stammler P, Jelezarova E, Nater M, Spath PJ. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3b(n)-IgG complexes. Blood 1996;88:184 93.
  • 31
    Miletic VD & Frank MM. Complement immunoglobulin interactions. Curr Opin Immunol 1995;7:41 7.
  • 32
    Bing DH. The interaction of immune serum globulin and immune globulin intravenous with complement. Mol Immunol 1983;20:893 900.